Table 1.
Patient characteristics at baseline.
| Population characteristics | N = 126 (%) |
|---|---|
| Median age, years [range] | 65 [29;86] |
| ECOG PS | |
| 0 | 50 (39.7) |
| 1 | 62 (49.2) |
| 2 | 12 (9.5) |
| 3 | 2 (1.6) |
| Histology at diagnosis | |
| Ductal | 94 (74.6) |
| Lobular | 29 (23.0) |
| Other | 3 (2.4) |
| SBR grade at diagnosis | |
| I | 18 (14.3) |
| II | 72 (57.1) |
| III | 32 (25.4) |
| Unknown | 4 (3.0) |
| Stage at diagnosis | |
| I | 13 (10.8) |
| II | 37 (30.8) |
| III | 34 (27) |
| IV | 36 (28.6) |
| Unknown | 6 (4.8) |
| Menopause | |
| Yes | 94 (74.6) |
| No | 32 (25.4) |
| De novo metastatic cancer | |
| Yes | 36 (28.6) |
| No | 90 (71.4) |
| Metastatic sites | |
| Locoregional only | 3 (2.4) |
| Bone only | 37 (29.4) |
| Others | 86 (68.3) |
| Adjuvant treatment a | |
| Yes | 87 (69) |
| No | 39 (31) |
| Radiotherapy within 90 days | |
| Yes | 30 (23.8) |
| No | 96 (76.2) |
| Corticosteroid therapy b | |
| Yes | 10 (7.9) |
| No | 116 (92.1) |
| Blood count (G/L; [range]) | |
| Neutrophils count | 3.46 [1.19;14.73] |
| Lymphocytes count | 1.44 [0.14;4.40] |
| Platelets count | 267 [101;622] |
| Monocytes count | 0.49 [0.10;1.30] |
| NLR (cut-off = 2.53) | |
| High | 64 (51) |
| Low | 62 (49) |
| Lymphopenia (< 1.5G/L) | |
| Yes | 67 (53) |
| No | 59 (47) |
| PLR (cut-off = 174.4) | |
| High | 68 (54) |
| Low | 58 (46) |
| LMR (cut-off = 3.3) | |
| High | 60 (48) |
| Low | 66 (52) |
ECOG-PS, Eastern Cooperative Oncology Group – Performance Status; SBR, Scarff-Bloom-Richardson; NLR, Neutrophil to Lymphocyte Ratio; PLR, Platelet to Lymphocyte Ratio; LMR, Lymphocyte to Monocyte Ratio.
a
including chemiotherapy and/or radiotherapy and/or endocrine therapy.
b
prior or at baseline.